Compass Therapeutics Investor Presentation Deck

CTX-8371: Differentiated MoA Leads to Enhanced T-Cell Activation Converting PD-1 positive T cells into PD-1 negative T cells PD-1 blockers release brake but don't directly promote T-cell activation APC or Tumor cell T-cell PD-L1 PD-1 -1- COMPASS THERAPEUTICS PD-L1 CD80 CD28 + + " + APC or Tumor cell PD-1 T-cell CTX-8371 activates T-Cells Through Multiple MOA's Significant reduction in cell surface PD-1 due to receptor shedding Bridging of PD-1 expressing T- cells with PD-L1 expressing APC's or tumor cells + + + + ## PD-L1 X PD-L1 Increased pool of free CD80 able to engage costimulatory receptor CD28 CD80 + + ↓↓ CD28 35

View entire presentation